AU2015349787B2 - Pneumolysin mutants and methods of use thereof - Google Patents

Pneumolysin mutants and methods of use thereof Download PDF

Info

Publication number
AU2015349787B2
AU2015349787B2 AU2015349787A AU2015349787A AU2015349787B2 AU 2015349787 B2 AU2015349787 B2 AU 2015349787B2 AU 2015349787 A AU2015349787 A AU 2015349787A AU 2015349787 A AU2015349787 A AU 2015349787A AU 2015349787 B2 AU2015349787 B2 AU 2015349787B2
Authority
AU
Australia
Prior art keywords
lys
ser
asn
val
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015349787A
Other languages
English (en)
Other versions
AU2015349787A1 (en
Inventor
Rodney K. Tweten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oklahoma
Original Assignee
University of Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oklahoma filed Critical University of Oklahoma
Publication of AU2015349787A1 publication Critical patent/AU2015349787A1/en
Application granted granted Critical
Publication of AU2015349787B2 publication Critical patent/AU2015349787B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
AU2015349787A 2014-11-21 2015-11-20 Pneumolysin mutants and methods of use thereof Active AU2015349787B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462082848P 2014-11-21 2014-11-21
US62/082,848 2014-11-21
PCT/US2015/061859 WO2016081839A1 (en) 2014-11-21 2015-11-20 Pneumolysin mutants and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2015349787A1 AU2015349787A1 (en) 2017-06-22
AU2015349787B2 true AU2015349787B2 (en) 2021-07-29

Family

ID=56014598

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015349787A Active AU2015349787B2 (en) 2014-11-21 2015-11-20 Pneumolysin mutants and methods of use thereof

Country Status (20)

Country Link
US (1) US10562941B2 (cg-RX-API-DMAC7.html)
EP (2) EP3220937B1 (cg-RX-API-DMAC7.html)
JP (1) JP6734274B2 (cg-RX-API-DMAC7.html)
KR (1) KR102304828B1 (cg-RX-API-DMAC7.html)
CN (1) CN107106635B (cg-RX-API-DMAC7.html)
AU (1) AU2015349787B2 (cg-RX-API-DMAC7.html)
DK (1) DK3220937T3 (cg-RX-API-DMAC7.html)
ES (1) ES2993430T3 (cg-RX-API-DMAC7.html)
FI (1) FI3220937T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241627T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069200T2 (cg-RX-API-DMAC7.html)
LT (1) LT3220937T (cg-RX-API-DMAC7.html)
MX (1) MX381872B (cg-RX-API-DMAC7.html)
PL (1) PL3220937T3 (cg-RX-API-DMAC7.html)
PT (1) PT3220937T (cg-RX-API-DMAC7.html)
RS (1) RS66221B1 (cg-RX-API-DMAC7.html)
SI (1) SI3220937T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400482T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016081839A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703881B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
EP3562838A2 (en) 2016-12-28 2019-11-06 Henriques Normark, Birgitta Microparticles from streptococcus pneumoniae as vaccine antigens
CN110967482B (zh) * 2018-09-30 2023-04-07 重庆市畜牧科学院 一种山羊化脓隐秘杆菌感染检测试剂盒及其检测方法
CN113264999B (zh) * 2021-04-29 2023-02-28 星济生物(苏州)有限公司 中和肺炎链球菌溶血素蛋白的抗原结合蛋白及其用途
CA3231684A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
KR20240149460A (ko) 2021-11-18 2024-10-14 매트리박스, 인크. 면역원성 융합 단백질 조성물 및 이의 사용 방법
CN115927420A (zh) * 2022-05-27 2023-04-07 贵州省畜牧兽医研究所 一种溶血素重组表达及间接elisa检测方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140341942A1 (en) * 2008-12-24 2014-11-20 Eliud Oloo Modified Streptococcus Pneumonia Pneumolysin (PLY) Polypeptides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
DE68929323T2 (de) 1988-12-16 2002-04-18 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
US6716432B1 (en) 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
US5854416A (en) 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
CA2221480A1 (en) 1995-06-07 1996-12-19 The Regents Of The University Of Minnesota Mutants of streptococcal toxin a and methods of use
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
WO2000005378A2 (en) 1998-07-22 2000-02-03 Id-Lelystad Instituut Voor Dierhouderij En Diergezondheid B.V. Streptococcus suis vaccines and diagnostic tests
DE69940439D1 (de) 1998-12-21 2009-04-02 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
US6887480B1 (en) 1999-06-10 2005-05-03 Medimmune, Inc. Streptococcus pneumoniae proteins and vaccines
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
US7217791B2 (en) 2002-11-07 2007-05-15 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
WO2005076696A2 (en) 2004-02-13 2005-08-25 Sanofi Pasteur Limited Pneumolysin derivatives
WO2005108419A1 (en) 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2007144647A2 (en) 2006-06-15 2007-12-21 Timothy John Mitchell Adjuvant compositions
CA2683748C (en) 2007-04-13 2016-02-16 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
US9649372B2 (en) * 2009-12-22 2017-05-16 Sanofi Pasteur Limited Immunogenic compositions and related methods
CL2010001216A1 (es) * 2010-11-08 2011-01-28 New Tech Copper S P A Sistema para confinar el espacio sobre el electrolito en una celda de electro obtencion y evacuar los aerosoles generados, que comprende un confinador insertado en cada anodo, con un par de proyecciones flexibles y un par de perfiles en angulo, y ductos longitudinales con perforaciones sobre el nivel del electrolito.
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
JP6397805B2 (ja) 2015-08-28 2018-09-26 東芝メモリ株式会社 半導体製造装置およびその運転方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140341942A1 (en) * 2008-12-24 2014-11-20 Eliud Oloo Modified Streptococcus Pneumonia Pneumolysin (PLY) Polypeptides

Also Published As

Publication number Publication date
EP3220937B1 (en) 2024-09-04
FI3220937T3 (fi) 2024-11-29
KR20170083635A (ko) 2017-07-18
EP4501949A3 (en) 2025-04-30
EP3220937A4 (en) 2018-05-30
SI3220937T1 (sl) 2025-03-31
ZA201703881B (en) 2021-10-27
DK3220937T3 (da) 2024-12-02
HRP20241627T1 (hr) 2025-02-14
CA2968398A1 (en) 2016-05-26
WO2016081839A1 (en) 2016-05-26
CN107106635B (zh) 2021-10-08
ES2993430T3 (en) 2024-12-30
KR102304828B1 (ko) 2021-09-27
PT3220937T (pt) 2024-11-18
EP3220937A1 (en) 2017-09-27
JP6734274B2 (ja) 2020-08-05
US20180312552A1 (en) 2018-11-01
BR112017010696A2 (pt) 2017-12-26
AU2015349787A1 (en) 2017-06-22
US10562941B2 (en) 2020-02-18
CN107106635A (zh) 2017-08-29
JP2017536124A (ja) 2017-12-07
MX2017006625A (es) 2018-01-15
HUE069200T2 (hu) 2025-02-28
EP4501949A2 (en) 2025-02-05
SMT202400482T1 (it) 2025-01-14
LT3220937T (lt) 2024-12-27
PL3220937T3 (pl) 2025-01-27
MX381872B (es) 2025-03-13
RS66221B1 (sr) 2024-12-31

Similar Documents

Publication Publication Date Title
AU2008287286B2 (en) Mutants of cholesterol-dependent cytolysins and uses thereof
AU2015349787B2 (en) Pneumolysin mutants and methods of use thereof
JP4874323B2 (ja) Ａ群連鎖球菌およびｂ群連鎖球菌由来の核酸およびタンパク質
JP4689044B2 (ja) ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
IL153558A (en) Streptococcus antigens
JP2009165468A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓタンパク質および核酸
US6833356B1 (en) Pneumococcal protein homologs and fragments for vaccines
JP4749641B2 (ja) ワクチン用の肺炎球菌タンパク質の相同体および断片
US20020110562A1 (en) Streptococcus pneumoniae proteins and vaccines
CA2968398C (en) Pneumolysin mutants and methods of use thereof
HK1237274A1 (en) Pneumolysin mutants and methods of use thereof
HK1237274B (en) Pneumolysin mutants and methods of use thereof
BR112017010696B1 (pt) Polipeptídeo de pneumolisina mutante purificada, composição imunogênica, métodos de preparo da dita composição imunogênica e uso do dito polipeptídeo para tratar, prevenir profilaticamente ou reduzir a ocorrência de uma condição, doença ou infecção causada por streptococcus pneumoniae
WO2004007725A9 (en) Polypeptide of streptococcus pyogenes
JP2005289966A (ja) Ａ群連鎖球菌およびｂ群連鎖球菌由来の核酸およびタンパク質

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)